TY - JOUR
T1 - Progression of Emphysema and Small Airways Disease in Cigarette Smokers
AU - Pompe, Esther
AU - Moore, Camille M.
AU - Mohamed Hoesein, Firdaus A.A.
AU - de Jong, Pim A.
AU - Charbonnier, Jean Paul
AU - Han, Mei Lan K.
AU - Humphries, Steven M.
AU - Hatt, Charles R.
AU - Galbán, Craig J.
AU - Silverman, Ed K.
AU - Crapo, James D.
AU - Washko, George R.
AU - Regan, Elisabeth A.
AU - Make, Barry
AU - Strand, Matthew
AU - Lammers, Jan Willem J.
AU - van Rikxoort, Eva M.
AU - Lynch, David A.
N1 - Funding Information:
The project described was supported by grants R01HL089897 and R01HL089856 from the National Heart, Lung, and Blood Institute. The Genetic Epidemiology of COPD (COPDGene) project is also supported by the COPD Foundation through contributions made to an industry advisory board representing AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion, and GlaxoSmithKline. In addition, this project has been financially supported by the Foundation “De Drie Lichten” in The Netherlands, the Lung Foundation Netherlands (grant 9.1.15.067FE), and the Foundation “Stichting Astma Bestrijding”.
Funding Information:
Sunovion, and GlaxoSmithKline. In addition, this project has been financially supported by
Funding Information:
project is also supported by the COPD Foundation through contributions made to an industry
Funding Information:
phases with royalties paid to Imbio. EK Silverman reports grants from NIH, grants and other
Publisher Copyright:
COPD Foundation © 2020
PY - 2021/4
Y1 - 2021/4
N2 - Background: Little is known about factors associated with emphysema progression in cigarette smokers. We evaluated factors associated with change in emphysema and forced expiratory volume in 1 second (FEV
1) in participants with and without chronic obstructive pulmonary disease (COPD).
Methods: This retrospective study included individuals participating in the COPD Genetic Epidemiology study who completed the 5-year follow-up, including inspiratory and expiratory computed tomography (CT) and spirometry. All paired CT scans were analyzed using micro-mapping, which classifies individual voxels as emphysema or functional small airway disease (fSAD). Presence and progression of emphysema and FEV
1 were determined based on comparison to nonsmoker values. Logistic regression analyses were used to identify clinical parameters associated with disease progression.
Results: A total of 3088 participants were included with a mean ± SD age of 60.7±8.9 years, including 72 nonsmokers. In all Global initiative for chronic Obstructive Lung Disease (GOLD) stages, the presence of emphysema at baseline was associated with emphysema progression (odds ratio [OR]: GOLD 0: 4.32; preserved ratio-impaired spirometry [PRISm]; 5.73; GOLD 1: 5.16; GOLD 2: 5.69; GOLD 3/4: 5.55; all
p ≤0.01). If there was no emphysema at baseline, the amount of fSAD at baseline was associated with emphysema progression (OR for 1% increase: GOLD 0: 1.06; PRISm: 1.20; GOLD 1: 1.7; GOLD 3/4: 1.08; all
p ≤ 0.03).In 1735 participants without spirometric COPD, progression in emphysema occurred in 105 (6.1%) participants and only 21 (1.2%) had progression in both emphysema and FEV
1.
Conclusions: The presence of emphysema is an important predictor of emphysema progression. In patients without emphysema, fSAD is associated with the development of emphysema. In participants without spirometric COPD, emphysema progression occurred independently of FEV
1 decline.
AB - Background: Little is known about factors associated with emphysema progression in cigarette smokers. We evaluated factors associated with change in emphysema and forced expiratory volume in 1 second (FEV
1) in participants with and without chronic obstructive pulmonary disease (COPD).
Methods: This retrospective study included individuals participating in the COPD Genetic Epidemiology study who completed the 5-year follow-up, including inspiratory and expiratory computed tomography (CT) and spirometry. All paired CT scans were analyzed using micro-mapping, which classifies individual voxels as emphysema or functional small airway disease (fSAD). Presence and progression of emphysema and FEV
1 were determined based on comparison to nonsmoker values. Logistic regression analyses were used to identify clinical parameters associated with disease progression.
Results: A total of 3088 participants were included with a mean ± SD age of 60.7±8.9 years, including 72 nonsmokers. In all Global initiative for chronic Obstructive Lung Disease (GOLD) stages, the presence of emphysema at baseline was associated with emphysema progression (odds ratio [OR]: GOLD 0: 4.32; preserved ratio-impaired spirometry [PRISm]; 5.73; GOLD 1: 5.16; GOLD 2: 5.69; GOLD 3/4: 5.55; all
p ≤0.01). If there was no emphysema at baseline, the amount of fSAD at baseline was associated with emphysema progression (OR for 1% increase: GOLD 0: 1.06; PRISm: 1.20; GOLD 1: 1.7; GOLD 3/4: 1.08; all
p ≤ 0.03).In 1735 participants without spirometric COPD, progression in emphysema occurred in 105 (6.1%) participants and only 21 (1.2%) had progression in both emphysema and FEV
1.
Conclusions: The presence of emphysema is an important predictor of emphysema progression. In patients without emphysema, fSAD is associated with the development of emphysema. In participants without spirometric COPD, emphysema progression occurred independently of FEV
1 decline.
KW - Air trapping
KW - Computed tomography
KW - COPD
KW - Emphysema
KW - computed tomography
KW - air trapping
KW - functional small airways disease
KW - emphysema
UR - http://www.scopus.com/inward/record.url?scp=85098777252&partnerID=8YFLogxK
U2 - 10.15326/JCOPDF.2020.0140
DO - 10.15326/JCOPDF.2020.0140
M3 - Article
C2 - 33290645
AN - SCOPUS:85098777252
SN - 2372-952X
VL - 8
SP - 198
EP - 212
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
IS - 2
ER -